Details of the Drug Combination

General Information of Drug Combination (ID: DC8P6ID)

Drug Combination Name
Amrubicin Lurbinectedin
Indication
Disease Entry Status REF
Small Cell Lung Cancer (SCLC) Phase 3 [1]
Component Drugs Amrubicin   DM6SGUB Lurbinectedin   DMEFRTZ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Amrubicin
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Phase 3 [2]
Amrubicin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Lurbinectedin
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [3]
leukaemia 2A60-2B33 Phase 3 [4]
Ovarian cancer 2C73 Phase 3 [4]
Endometrial cancer 2C76 Phase 2 [5]
Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
Lurbinectedin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid minor groove (hDNA min) TTOVXHF NOUNIPROTAC Inhibitor [3]
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Inhibitor [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Small Cell Lung Cancer DC37XA4 N. A. Phase 3 [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05740566) Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
2 ClinicalTrials.gov (NCT00547651) AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy. U.S. National Institutes of Health.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
7 ClinicalTrials.gov (NCT06203210) A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer